SignalXSignalX

CYTK CYTOKINETICS INC

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
CYTOKINETICS INC Overview

CYTOKINETICS INC (CYTK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New regulatory risk: FDA workforce reductions and government shutdowns may delay NDA approval this quarter, with aficamten PDUFA date extended to Dec 26, 2025
  • • Updated clinical risk: discontinuation of COURAGE-ALS Phase 3 trial due to futility signals increased uncertainty in drug efficacy demonstration
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2M

Net Income

-$306M

Operating Margin

-8613.4%

Net Margin

-15815.0%

ROE

58.8%

Total Assets

$1.4B

Source: XBRL data from CYTOKINETICS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on CYTOKINETICS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.